MDWD (MediWound) Inventories, Raw Materials & Components: $0.00 Mil (As of Mar. 2026)

MediWound MDWD +2.19% 56 Inventories, Raw Materials & Components is $0.00 Mil as of Mar. 2026. GuruFocus rates MDWD with a GF Score™ of 56/100 and a GF Value™ of $12.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

MediWound's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $0.00 Mil.

MediWound's quarterly raw materials increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($1.72 Mil) but then declined from Dec. 2025 ($1.72 Mil) to Mar. 2026 ($0.00 Mil).

MediWound's annual raw materials increased from Dec. 2023 ($1.00 Mil) to Dec. 2024 ($1.44 Mil) and increased from Dec. 2024 ($1.44 Mil) to Dec. 2025 ($1.72 Mil).

MediWound Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for MediWound's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediWound Inventories, Raw Materials & Components Chart

MediWound Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

0.69

0.91

1.00

1.44

1.72

MediWound Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															0.00	0.00	0.00	1.72	0.00

56GF Score

MediWound Ltd MDWD

Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

MediWound Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Frequently Asked Questions Learn more about Inventories, Raw Materials & Components →

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?

MediWound (MDWD) has a Inventories, Raw Materials & Components of $0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on MediWound and its competitors.

Is MediWound's Inventories, Raw Materials & Components too high?

MediWound's current Inventories, Raw Materials & Components is $0.00 Mil. Overall, MediWound has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does MediWound's Inventories, Raw Materials & Components compare to UNCY and ARCT?

MediWound's Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventories, Raw Materials & Components for a Biotechnology company?

A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventories, Raw Materials & Components mean?

A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on MediWound and its competitors. MediWound's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is MediWound stock overvalued right now?

Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.44, compared to a current price of $15.16 — trading 21.9% above its estimated fair value. The current Inventories, Raw Materials & Components is $0.00 Mil. MediWound's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventories, Raw Materials & Components calculated?

Inventories, Raw Materials & Components is calculated from a company's financial statements. For MediWound (MDWD), the current Inventories, Raw Materials & Components is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediWound (MDWD) Overvalued in 2026?

Based on GuruFocus' analysis, MediWound stock appears to be overvalued. The current stock price of $15.16 is trading 21.9% above its estimated GF Value™ of $12.44. GuruFocus considers MediWound to be Modestly Overvalued.

Key valuation signals for MDWD:

Inventories, Raw Materials & Components: $0.00 Mil
GF Value™: $12.44 vs. price of $15.16 (21.9% above fair value)
GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediWound Business Description

Industry Healthcare Biotechnology

Comparable Companies UNCY ARCT NGEN EQ ORMP HUMA NBP NKTX DTIL NERV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges M8W:Germany

Address 42 Hayarkon Street, Yavne, ISR, 8122745

Website https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

56GF Score

Get the complete analysis for MDWD

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16

Price

$12.44

GF Value

View MDWD Analysis

See Inventories, Raw Materials & Components data for all stocks →